Μετάβαση στο περιεχόμενο

ΕτικέταKeytruda

Merck’s Keytruda Nabs Another Approval, This One Under FDA’s Real-Time Program

The U.S. Food and Drug Administration (FDA) granted Merck & Co.’s Keytruda another approval, this one in combination with Alimta (pemetrexed) and platinum chemotherapy for first-line treatment of metastatic non-small cell lung cancer (NSCLC), with … Continue Reading Merck’s Keytruda Nabs Another Approval, This One Under FDA’s Real-Time Program

Bristol-Myers Squibb’s Opdivo Gets New Approval for Lung Cancer Indication

The U.S. Food and Drug Administration (FDA) gave Bristol-Myers Squibb’s Opdivo (nivolumab) approval for metastatic small cell lung cancer (SCLC) for patients whose cancer has progressed after platinum-based chemotherapy and at least one other type of … Continue Reading Bristol-Myers Squibb’s Opdivo Gets New Approval for Lung Cancer Indication

Bristol-Myers Squibb’s Opdivo-Yervoy combo wins right to challenge Merck’s Keytruda in rare cancer

Tally another win for Bristol-Myers Squibb’s immunotherapy combination. Wednesday, the New Jersey drugmaker said its Opdivo-Yervoy pairing grabbed an FDA approval in patients with rare colon cancers that have progressed despite other … Continue Reading Bristol-Myers Squibb’s Opdivo-Yervoy combo wins right to challenge Merck’s Keytruda in rare cancer

ASCO: Bristol-Myers racks up Opdivo combo data to sell its new biomarker, but will doctors buy it?

CHICAGO—Bristol-Myers Squibb’s new strategy In lung cancer relies on showing its new biomarker can help predict who benefits most from immunotherapy combinations. And Monday at the American Society of Clinical Oncology annual … Continue Reading ASCO: Bristol-Myers racks up Opdivo combo data to sell its new biomarker, but will doctors buy it?